Intuitive Surgical (NASDAQ:ISRG) Trading 0.1% Higher – Here’s Why

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) rose 0.1% during mid-day trading on Tuesday . The stock traded as high as $599.00 and last traded at $596.42. Approximately 355,600 shares traded hands during trading, a decline of 79% from the average daily volume of 1,707,671 shares. The stock had previously closed at $595.55.

Analysts Set New Price Targets

ISRG has been the subject of several analyst reports. Evercore ISI lifted their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. BTIG Research lifted their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Truist Financial boosted their target price on shares of Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Finally, Barclays boosted their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Performance

The firm’s 50-day moving average price is $560.61 and its 200 day moving average price is $521.21. The company has a market cap of $214.12 billion, a price-to-earnings ratio of 93.79, a PEG ratio of 5.67 and a beta of 1.39.

Insider Activity at Intuitive Surgical

In related news, CFO Jamie Samath sold 108 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the transaction, the chief financial officer now owns 8,757 shares in the company, valued at approximately $4,746,819.42. The trade was a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 408 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total transaction of $240,618.00. Following the transaction, the executive vice president now owns 353 shares of the company’s stock, valued at approximately $208,181.75. This represents a 53.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,348 shares of company stock worth $3,587,582. 0.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ISRG. Atala Financial Inc bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $25,000. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $26,000. Parvin Asset Management LLC bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $28,000. Finally, Hurley Capital LLC bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.